Patient characteristics by medical conditions pre-and post-prescription law. by Megan Armstrong (1782073)

Opioid medication use and patient satisfaction after hospital discharge. by Megan Armstrong (1782073)

Number of days and MMEs/kg prescribed at discharge by days to law change. by Megan Armstrong (1782073)

Examples of lesions identified in H&E-stained tissues. by Özgün Le Roux (18271992)

Stress strain curves (from a1 to f1), stress—AE count plots (from a2 to f2) and stress—cumulative AE count plots (from a3 to f3) for the sample temperatures of 20°C, 50°C, 100°C, 1... by Nazlı Tunar Özcan (14833635)

Data on 1pre-treatment1 and 1post-treatment1tracking1tiles1 that indicate a decrease in rodent activity due to 12% zinc11pphosphide mixed1 in bait1 base (millet-wheat 11:10 with 15... by Durr e Shahwar (17798007)

[Fourier Transform Infrared spectroscopy (FTIR) as a screening method for freezing point in raw milk] by E. Duarte (10387469)

Imaging from a man in his 50s diagnosed with World Health Organization grade III oligodendroglioma. by Qing Wang (27728)

Structural details for each point mutation studied by X-ray crystallography in this study. by Aleksi Sutinen (10039145)

Development of (2-(Benzyloxy)phenyl)methanamine Derivatives as Potent and Selective Inhibitors of CARM1 for the Treatment of Melanoma by Zhihao Liu (419349)

“…In our previous study, we have identified a series of type I PRMT inhibitors, among which ZL-28-6 (<b>6</b>) exhibited increased activity against CARM1 while displaying decreased potency against other type I PRMTs. …”

Development of (2-(Benzyloxy)phenyl)methanamine Derivatives as Potent and Selective Inhibitors of CARM1 for the Treatment of Melanoma by Zhihao Liu (419349)

“…In our previous study, we have identified a series of type I PRMT inhibitors, among which ZL-28-6 (<b>6</b>) exhibited increased activity against CARM1 while displaying decreased potency against other type I PRMTs. …”

Development of (2-(Benzyloxy)phenyl)methanamine Derivatives as Potent and Selective Inhibitors of CARM1 for the Treatment of Melanoma by Zhihao Liu (419349)

“…In our previous study, we have identified a series of type I PRMT inhibitors, among which ZL-28-6 (<b>6</b>) exhibited increased activity against CARM1 while displaying decreased potency against other type I PRMTs. …”

Association of polymorphic IC_50s versus wild<i>-</i>type at codon 876 in selected drugs tested. by Winnie Okore (14139712)

A Wearable Dual-Modal Patch for Rapid Pre-Hospital Diagnosis of Acute Myocardial Infarction by Kuo Yang (280921)

“…The time required for diagnosing ischemia was significantly reduced to 50 min after its onset. The patch is optimally integrated into a stamp-sized band-aid, accompanied by a smartphone app for data visualization and real-time analysis. …”

A Wearable Dual-Modal Patch for Rapid Pre-Hospital Diagnosis of Acute Myocardial Infarction by Kuo Yang (280921)

“…The time required for diagnosing ischemia was significantly reduced to 50 min after its onset. The patch is optimally integrated into a stamp-sized band-aid, accompanied by a smartphone app for data visualization and real-time analysis. …”

A Wearable Dual-Modal Patch for Rapid Pre-Hospital Diagnosis of Acute Myocardial Infarction by Kuo Yang (280921)

“…The time required for diagnosing ischemia was significantly reduced to 50 min after its onset. The patch is optimally integrated into a stamp-sized band-aid, accompanied by a smartphone app for data visualization and real-time analysis. …”

First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation by Kairui Yue (11874403)

“…Low-dose <b>35m</b> remarkably decreases LPS-induced IL-1β release both <i>in vitro</i> and <i>in vivo</i> by blocking the activation of NLRP3, indicating that <b>35m</b> can be a potential orally active therapeutic agent for the treatment of NLRP3-related diseases.…”

First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation by Kairui Yue (11874403)

“…Low-dose <b>35m</b> remarkably decreases LPS-induced IL-1β release both <i>in vitro</i> and <i>in vivo</i> by blocking the activation of NLRP3, indicating that <b>35m</b> can be a potential orally active therapeutic agent for the treatment of NLRP3-related diseases.…”

Characteristics of patients with AKI diagnosed using eKDIGO only by the decrease in sCr (deKDIGO) and no AKI. by Marina Wainstein (12437091)

HPLC replicates of DAM-1 as standard and comparison view of DAM-1, <i>E</i>.<i>coli</i> + DAM-1 and solvent blank. by Manoj Limbraj Yellurkar (11467219)